You are here

Share:

Bac-2-the-Future: An Improved System for Production of Recombinant Baculovirus

Summary
The National Cancer Institute (NCI) seeks licensing of Bac-2-the-Future, an improved system for the production of recombinant baculovirus.
NIH Reference Number
E-287-2012
Product Type
Keywords
  • Baculovirus, Protein Production, B2F, Bac-2-the-Future, Insect Cells, Esposito
Collaboration Opportunity
This invention is available for licensing.
Contact
Description of Technology

Baculoviruses have been used for decades to produce proteins in insect cell hosts. Current systems for generating recombinant baculovirus have several shortcomings which prevent their easy use in high-throughput applications. 

Researchers within the Frederick National Laboratory for Cancer Research have developed an improved system called Bac-2-the-future, or B2F, to quickly and efficiently generate recombinant baculoviruses which produce recombinant proteins. In the new system, the baculovirus transfer vector, transposition helper plasmid, and E. coli strain carrying the bacmid DNA were modified to eliminate the need for screening positive clones and improve the efficiency of baculovirus production. Taken together, these improvements permit facile high-throughput recombinant baculovirus production at reduced cost and improved speed over the currently available systems.  The new transfer vectors and E. coli strains of the B2F system are available for licensing.  

Potential Commercial Applications
  • High-throughput protein production
  • Generation of virus-like particles in insect cells
Competitive Advantages
  • Elimination of background plasmid DNA during recombinant baculovirus production
  • Elimination of nonproductive transposition events leading to false positives
  • Lower cost production of baculovirus
  • Increased speed of baculovirus production (allowing high-throughput production with limited screening)
  • Higher efficiency cloning of baculovirus constructs
Development Stage
Publications

Mehalko JL, et al.  Engineering the transposition-based baculovirus expression vector system for higher efficiency protein production from insect cells.  [PMID 27616621]

Patent Status
  • Research Material: NIH will not pursue patent prosecution for this technology
Related Technologies
  • E-164-2011
Therapeutic Area
Updated
Monday, October 1, 2018